Adalimumab Biosimilar Market Size, Share Analysis | 2034

Adalimumab Biosimilar Market Overview

The global adalimumab biosimilar market is witnessing rapid expansion due to the rising incidence of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. As the patent expiry of Humira, the world’s top-selling drug, opens opportunities, biosimilars are being increasingly developed to provide cost-effective treatment alternatives. The growing geriatric population, higher prevalence of chronic conditions, and increasing healthcare expenditure are driving demand. Moreover, supportive regulatory frameworks and approvals in multiple regions are fueling adoption. Pharmaceutical companies are heavily investing in biosimilar R&D, ensuring wider accessibility to adalimumab biosimilars across global healthcare systems.

Adalimumab Biosimilar Market Size

The adalimumab biosimilar market is projected to grow at a robust CAGR of 17.60% during 2025–2034. This strong growth is attributed to increased approvals, patent expirations, and cost-effectiveness of biosimilars compared to biologics. In 2024, the market already gained significant momentum as multiple biosimilars entered developed markets such as the United States and Europe. By 2034, the market is expected to generate substantial revenues as demand accelerates in emerging economies with rising healthcare access. The affordability of biosimilars will play a vital role in expanding patient reach, reducing treatment burden, and reshaping the global biologics landscape.

Adalimumab Biosimilar Market Share

The adalimumab biosimilar market share is dominated by pharmaceutical giants with established portfolios and regulatory approvals. Companies like Amgen, Boehringer Ingelheim, and Glenmark have secured strong positions by leveraging extensive clinical research and market penetration strategies. Europe currently holds a leading share due to early biosimilar adoption, while North America is rapidly gaining momentum after Humira’s patent expiration. Emerging economies in Asia-Pacific are expected to increase their share significantly, driven by local manufacturers such as Cadila and Torrent Pharmaceuticals. The competitive landscape remains dynamic, with both multinational and regional players vying for greater global presence.

Adalimumab Biosimilar Market Trends

Key trends in the adalimumab biosimilar market include the rapid expansion of biosimilar approvals in the U.S. and EU, increased adoption in emerging markets, and price competition driving affordability. Strategic partnerships between global pharmaceutical companies and regional players are enhancing distribution networks. Additionally, growing physician and patient awareness about biosimilars’ safety and efficacy is boosting confidence. Digital marketing and telemedicine platforms are being used to expand outreach. Another emerging trend is government incentives for biosimilar development and integration into public healthcare systems, ensuring broader patient access while reducing healthcare expenditure. These trends position the market for sustained growth.

Adalimumab Biosimilar Market Analysis

The adalimumab biosimilar market analysis highlights a rapidly evolving industry driven by rising demand for affordable biologics. With Humira’s market exclusivity ending in key regions, biosimilars are witnessing exponential uptake. The high cost of biologics has historically limited patient access, creating opportunities for biosimilars to bridge treatment gaps. Regulatory bodies like the FDA and EMA have accelerated approvals, ensuring strong competition among leading players. Pricing pressure remains a critical factor, with companies adopting competitive pricing strategies to gain market entry. Furthermore, increasing prevalence of rheumatoid arthritis and inflammatory bowel diseases, particularly in aging populations, is expanding the treatment base. The market also benefits from technological advancements in biologic manufacturing, enabling better scalability and quality assurance. However, challenges such as patient switching reluctance, regulatory complexities in emerging markets, and brand loyalty to originators persist. Overall, the analysis underscores a robust growth trajectory with biosimilars reshaping the biologics ecosystem.

Adalimumab Biosimilar Market Segmentation

The adalimumab biosimilar market segmentation can be classified as follows:

By Indication

• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Crohn’s Disease
• Ulcerative Colitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End-User

• Hospitals
• Specialty Clinics
• Homecare Settings

By Region

• North America: Rapid growth post-Humira patent expiration.
• Europe: Early adoption and strong biosimilar penetration.
• Asia-Pacific: Increasing healthcare access and domestic manufacturing.
• Latin America & Middle East: Growing demand for cost-effective therapies.

This segmentation reflects the diverse applications and expanding accessibility of adalimumab biosimilars across multiple therapeutic areas and global regions.

Claim a Free Report Sample Along with the Table of Contents

Adalimumab Biosimilar Market Growth

The adalimumab biosimilar market growth is fueled by the rising prevalence of autoimmune diseases and the need for affordable treatment options. Increasing adoption across developed and developing economies, coupled with favorable regulatory support, is driving market expansion. With a CAGR of 17.60% during 2025–2034, the market is expected to achieve remarkable growth levels. Investments in advanced biologic manufacturing, collaborations between global and regional players, and strategic product launches are further accelerating growth. Moreover, greater patient and physician acceptance of biosimilars will contribute significantly to expanding market size and enhancing global accessibility to biologic therapies.

Recent Developments and Challenges in the Adalimumab Biosimilar Market

Recent years have witnessed significant developments in the adalimumab biosimilar market. Multiple biosimilars received FDA and EMA approvals, enabling entry into key markets. Partnerships between global pharma giants and local manufacturers are enhancing production capabilities and distribution networks. Additionally, competitive pricing strategies are reshaping cost dynamics in biologics. Digital awareness campaigns are also strengthening physician and patient confidence in biosimilars.

However, the market faces challenges such as regulatory hurdles in emerging economies, patient reluctance to switch from originator biologics, and complex manufacturing processes. Pricing pressures, while ensuring affordability, reduce profit margins for manufacturers. Furthermore, ongoing patent disputes and brand loyalty to Humira may slow biosimilar adoption in some regions. Despite these challenges, rising global demand for cost-effective biologics ensures that the adalimumab biosimilar market will continue to witness strong momentum over the coming years.

Key Players in the Adalimumab Biosimilar Market

Prominent companies operating in the adalimumab biosimilar market include:

• Alfred E. Tiefenbacher (GmbH & Co. KG)
• Amgen Inc.
• Boehringer Ingelheim Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• Cadila Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Reliance Life Sciences Private Limited
• Others